Quorum Review IRB Establishes an East Coast Ethics Board Focused on Oncology
Quorum Review IRB
is introducing a new ethics board located in Cambridge, Massachusetts. This panel includes members from academia with significant expertise in oncology research. The Cambridge Board will begin reviewing studies on October 4, 2011. Quorum will continue to hold eight board meetings each week.
Oncology is a complex, fast-moving, and innovative area of clinical research. With this panel, researchers can benefit from IRB members with years of experience in oncology treatment and research. Quorum’s broad range of therapeutic expertise will also be supported as members are affiliated with a range of institutions, including Harvard Medical School, Dana Farber, Tufts, and Boston University.
The Cambridge Board will meet weekly. Researchers may also submit oncology studies to the next available Board meeting, as Quorum always includes oncology expertise on a panel when a cancer study is presented for review.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
